Used in the treatment of B-cell non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and other B-cell malignancies. Targets CD20 antigen on the surface of B cells, leading to cell destruction through mechanisms like antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis. Also used in autoimmune diseases such as rheumatoid arthritis, where it helps reduce disease activity by depleting abnormal B cells involved in immune system attacks on joints. Serves as a reference standard in bioanalytical assays and biosimilar development to ensure consistency and efficacy in therapeutic antibody products.